Medtronic (NYSE:MDT) today announced expanded paid family leave benefits which the company says will “allow for greater employee flexibility while balancing work and family priorities.” The new benefits, which went into effect today, cover full and part-time US employees and allow for a “wide range of family care leave needs,” the Fridley, Minn.-based company said. These […]
C.R. Bard
UPDATE: New Jersey jury hits BD subsidiary Bard with $68m pelvic mesh verdict
Updated to include a $35 million punitive damages verdict released today. Becton Dickinson & Co. (NYSE:BDX) subsidiary C.R. Bard was reportedly hit yesterday with a $33 million verdict in a product liability lawsuit brought over its Avaulta and Align pelvic mesh products. A New Jersey jury in the Bergen County Superior Court awarded $23 million in compensatory […]
BD’s C.R. Bard must pay $4m in IVC bellwether
Becton Dickinson & Co.’s (NYSE:BDX) C.R. Bard (NYSE:BCR) is on the hook for $3.6 million in damages after a federal jury in Phoenix found Bard liable for damages caused by inferior vena cava filtering devices. The case is the first bellwether trial out of more than 3,000 suits which have been filed against Bard related to IVC […]
Bard wins 3DMax hernia mesh appeal
The New Jersey Superior Court’s Appellate Division this week tossed a win to Becton Dickinson & Co.‘s (NYSE:BDX) C.R. Bard (NYSE:BCR), refusing to reinstate a hernia mesh product liability suit on grounds that expert witnesses couldn’t prove the design of the product was defective or that significant negligence occurred. In the case, plaintiff Kemuel Goodson claims that […]
Veryan’s helical stent meets safety, efficacy endpoints after 12 months
Veryan‘s helical BioMimics 3D stent met its primary safety and efficacy endpoints in a study of 271 patients with symptomatic femoropopliteal artery disease, according to TCTMD. The device, which is shaped to mimic the natural geometry of human vasculature, compared favorably with drug-coated balloons and stents. The probability of maintaining primary patency after 12 months was […]
Bard escapes hernia mesh lawsuit
Becton Dickinson & Co.‘s (NYSE:BDX) C.R. Bard (NYSE:BCR) and subsidiary Davol this week avoided a lawsuit over allegedly defective hernia meshes after an appellate panel reaffirmed a lower court’s dismissal. The lower court had dismissed the suit on the grounds that the operating physician in the case was informed of risks associated with the mesh, eliminating […]
BD closes $24B Bard buy-out
Becton Dickinson & Co. (NYSE:BDX) said today that it completed its buy-out of C.R. Bard (NYSE:BCR). The combined company boasts $16 million in yearly revenue. The $317-per-share deal was first announced in April and in the past few months won conditional approval in the E.U., the U.S. and China. “Today is a historic day for BD as […]
BD wins Chinese clearance for Bard buy, expects to close tomorrow
Becton Dickinson (NYSE:BDX) said today that China’s Ministry of Commerce has cleared its acquisition of C. R. Bard (NYSE:BCR), and that the deal is expected to close tomorrow. The news comes only a day after the company said that the US’s Federal Trade Commission gave the go-ahead to the merger, with the caveat that it divests of […]
FTC clears BD’s Bard acquisition
The U.S.’s Federal Trade Commission has given Becton Dickinson (NYSE:BDX) the green light to go through with its C. R. Bard (NYSE:BCR) acquisition, as long as it divests of its soft-tissue core needle biopsy product line and Bard’s Aspira tech. “FTC approval brings us one step closer to full regulatory clearance of the Bard acquisition,” BD chairman & […]
BD tacks 5-day extension onto Bard note tender offer
Becton Dickinson (NYSE:BDX) said today it will tack another extension onto its tender offer for up to $1.1 billion in outstanding C. R. Bard (NYSE:BCR) notes, pushing the deadline back from December 14 to December 19. The company announced the initial $317-per-share deal in April, and expects to see it close during the fourth quarter. BD won conditional EU approval for […]
BD tacks another extension onto Bard tender offer
Becton Dickinson (NYSE:BDX) today announced yet another extension to its tender offer for up to $1.1 billion in outstanding C. R. Bard (NYSE:BCR) notes, pushing the deadline back from November 28 to December 14. The $317-per-share deal, announced last April, is expected to close during the fourth quarter. BD won conditional EU approval for the deal last month. BD is offering to buy […]